Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Prostate cancer - to screen or not to screen?

This article was originally published in Clinica

Executive Summary

Prostate cancer imposes a significant burden on society, both in terms of the individual suffering it causes and the demands it places on healthcare systems. Last year, approximately 192,000 men were diagnosed with prostate cancer in the US alone, and the number of deaths from the disease was estimated at around 27,000. All told, some 2.2 million men in the US are living with prostate cancer, and in many of these patients the tumour will have metastasised, often to bone, which can be painful and debilitating.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT058893

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel